What is it about?
This review explores a promising approach to improve radioactive drugs used to treat advanced prostate cancer. These drugs target a protein called PSMA, which is found at high levels on many prostate cancer cells. By adding a small chemical group derived from 4-phenylbutyric acid, researchers can make these drugs temporarily bind to albumin, a protein naturally present in the blood. We explain how this modification affects drug behavior in the body and summarize findings from laboratory research and early clinical studies.
Featured Image
Photo by julien Tromeur on Unsplash
Why is it important?
Current PSMA-targeted radioactive drugs can be eliminated from the body relatively quickly, limiting the radiation delivered to tumors. Binding to albumin allows these drugs to circulate longer, potentially increasing their accumulation in cancer cells and improving treatment effectiveness. However, prolonged circulation may also increase radiation exposure to healthy organs, particularly the kidneys and bone marrow. Finding the right balance between effectiveness and safety is therefore essential.
Perspectives
Several promising albumin-binding drugs have entered clinical evaluation, but larger studies are needed to confirm their benefits and long-term safety. Future research should focus on optimizing their chemical structures to maximize tumor targeting while minimizing unwanted radiation exposure. This approach could also support the development of new treatments using different radioactive elements, particularly alpha emitters, and potentially improve outcomes for patients with advanced prostate cancer.
Cyril Fersing
Institut regional du Cancer de Montpellier
Read the Original
This page is a summary of: Radionuclide Therapy of Prostate Cancer Using PSMA Ligands with a 4-Phenylbutyric Acid-Derived Albumin Binder: Recent Chemical and Clinical Advances, Current Medicinal Chemistry, July 2026, Bentham Science Publishers,
DOI: 10.2174/0109298673477106260706142910.
You can read the full text:
Contributors
The following have contributed to this page
